The National Institute for Health and Care Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Prostate artery embolisation for benign prostatic hyperplasia.
Benign prostatic hyperplasia (BPH) is a condition that causes the prostate to increase in size. This can block or narrow the tube that urine passes through to leave the body. The symptoms of BPH include urination problems, such as having a weak stream of urine, being unable to empty the bladder, and having to get up frequently in the night to urinate. Prostate artery embolisation for BPH involves injecting small particles into the blood vessels that supply the prostate. This blocks the blood supply, with the aim of shrinking the prostate.
L71.3 Percutaneous transluminal embolisation of artery
Y53.- Approach to organ under image control
Z38.8 Specified terminal branch of aorta NEC
Note: Codes within category Y53.- are used as secondary codes to classify interventions that are percutaneous and require some form of image control: if the method of image control is unspecified, Y53.9 Unspecified approach to organ under image control is assigned.
In addition the ICD-10 code N40.X Hyperplasia of prostate would be assigned.
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.